Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus-derived exosomes
- Development stage
- Preclinical
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intraperitoneal
01
Overview
Lactobacillus rhamnosus-derived exosomes (LREs) are microbiota-derived extracellular vesicles being investigated for the treatment of therapy-resistant Head and Neck Squamous Cell Carcinoma (HNSCC). These exosomes exert anti-tumor activity by targeting both the bulk tumor population and the cancer stem cell (CSC) niche. Mechanistically, LREs induce dual cell death pathways—apoptosis and ferroptosis—while simultaneously suppressing stemness markers such as SOX2, NANOG, and CD44. They also reverse the epithelial-mesenchymal transition (EMT) phenotype, evidenced by the upregulation of E-cadherin and downregulation of Vimentin. Preclinical studies indicate that LREs exhibit synergistic effects with cisplatin and show enhanced efficacy in HPV-positive HNSCC subtypes, regardless of p53 status.
- Other names
- Lactobacillus-derived exosomesL. rhamnosus-derived exosomes
02
Targets
AHR (Aryl hydrocarbon receptor)
Beyond the preview
Go deeper on lactobacillus rhamnosus-derived exosomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus-derived exosomes.